Angelman Syndrome Market is Projected to Advance at a Significant CAGR During the Forecast Period (2019-32) | Key Companies - StrideBio, Ovid Therapeutics, PTC Therapeutics, GeneTx Biotherapeutics, Sarepta Therapeutics, and others

DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Angelman Syndrome Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Angelman Syndrome market report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Angelman Syndrome: An Overview
Angelman syndrome (AS) is a complex genetic disorder that primarily affects the nervous system. The characteristic features of this condition include delayed development, intellectual disability, severe speech impairment, and problems with movement and balance (ataxia). Most affected children also have recurrent seizures (epilepsy) and small head sizes (microcephaly). Delayed development becomes noticeable by the age of 6 to 12 months, and other common signs and symptoms usually appear in early childhood.

Angelman Syndrome Market Key Facts
The total prevalent population of Angelman syndrome in the seven major markets was 58,350+ in 2017 which constituted both live-birth cases as well as adult prevalent cases.
The estimated prevalence of Angelman syndrome in the United States was 21,990+ in 2017.
The United States accounts for the largest market size of Angelman syndrome, in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
Among the EU5 countries, Germany had the highest prevalent population of Angelman syndrome with 6,670+ cases and Spain had the lowest prevalent population of 3,760+ cases in 2017.
As per the study conducted by Charles A. Williams et al., the prevalence of Angelman syndrome is estimated to be 1/15,000 cases.

Find a sample copy of the Angelman Syndrome Market report at:
https://www.delveinsight.com/sample-request/angelman-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Angelman Syndrome Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Angelman Syndrome market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Angelman Syndrome market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Request a sample and discover more about the report offerings:
https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Angelman Syndrome Epidemiology
The epidemiology section covers detailed insights into the historical and current Angelman Syndrome patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

Explore more about the Angelman Syndrome Epidemiology: https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Angelman Syndrome Epidemiology Segmentation
Total Prevalent Cases of Angelman syndrome
Live Birth Cases of Angelman syndrome
Adult Prevalent Cases of Angelman syndrome
Diagnosed Prevalent Cases of Angelman syndrome
Angelman syndrome cases by Mutation Types
Angelman syndrome associated Clinical Manifestations

Angelman Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Angelman Syndrome market or expected to get launched in the market during the study period. The analysis covers Angelman Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake, and the reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Angelman Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for a sample report to understand more about the Angelman Syndrome pipeline development activities:
https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Angelman Syndrome Therapeutics Assessment
Angelman Syndrome Therapeutics Pipeline is not robust. To counter the current unmet needs of the market and to provide better treatment options for Angelman syndrome. With the ongoing research studies at both the industry and university levels, the future of Angelman syndrome treatment seems promising. Research for future treatment options is focused on gene therapies, topoisomerase inhibitors, minocycline, cannabidiols, and PP2A inhibitors (LB-100).

Some of the key companies in the Angelman Syndrome market include:
StrideBio
Ovid Therapeutics
PTC Therapeutics
GeneTx Biotherapeutics
Sarepta Therapeutics
And others.

Angelman Syndrome Therapies covered in the report include:
Gaboxadol (OV101)
GTX-101 and GTX-102
GT-AS/AGIL-AS
And many others.

Learn more about the emerging therapies & key companies in the Angelman Syndrome Therapeutics Market:
https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Angelman Syndrome Competitive Intelligence Analysis
4. Angelman Syndrome Market Overview at a Glance
5. Angelman Syndrome Disease Background and Overview
6. Angelman Syndrome Patient Journey
7. Angelman Syndrome Epidemiology and Patient Population
8. Angelman Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Angelman Syndrome Unmet Needs
10. Key Endpoints of Angelman Syndrome Treatment
11. Angelman Syndrome Marketed Products
12. Angelman Syndrome Emerging Therapies
13. Angelman Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Angelman Syndrome Market Outlook (7 major markets)
16. Angelman Syndrome Access and Reimbursement Overview
17. KOL Views on the Angelman Syndrome Market.
18. Angelman Syndrome Market Drivers
19. Angelman Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Angelman Syndrome Market report here:
https://www.delveinsight.com/sample-request/angelman-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.